Improved quality of life in patients with GEP-NETs treated with 177Lu-dotatate

被引：0
|
作者：
Saravana-Bawan, B. [1 ]
Wieler, M. [2 ]
McMullen, T. [1 ]
McEwan, A. [2 ]
机构：
[1] Univ Alberta, Dept Surg, Edmonton, AB, Canada
[2] Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
基金：
加拿大健康研究院; 加拿大创新基金会;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1327P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Improved Quality of Life in Patients With GEP-NETs Treated With 177Lu-DOTATATE
    Saravana-Bawan, Bianka
    Wieler, Marguerite
    McMullen, Todd
    McEwan, Alexander
    PANCREAS, 2019, 48 (03) : 450 - 450
  • [2] Evaluation of RadioLigand Therapy response in GEP-NETs: the role of 177Lu-Dotatate imaging
    Valente, S.
    Linguanti, F.
    Abenavoli, M. E.
    Antonuzzo, L.
    Briganti, V.
    Lavacchi, D.
    Matteini, M.
    Mungai, F.
    Sciagra, R.
    Simontacchi, G.
    Vaggelli, L.
    Berti, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S647 - S647
  • [3] Single-institution real-life experience of 177Lu-DOTATATE treatment in progressive, well-differentiated GEP-NETs
    Scalorbi, F.
    Maccauro, M.
    Lorenzoni, A.
    Fuoco, V
    Argiroffi, G.
    Prinzi, N.
    Pusceddu, S.
    Coppa, J.
    De Braud, F.
    Milione, M.
    Mazzaferro, V
    Seregni, E.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 195 - 195
  • [4] Increased Tumor Size and Progression Free Survival after 177Lu-DOTATATE for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
    Patel, J.
    Zhang, K.
    Gbolahan, O. B.
    Schuster, D. M.
    Muzahir, S.
    Patel, P. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E477 - E478
  • [5] HAEMATOLOGICAL AND RENAL TOXICITY IN PATIENTS WITH PROGRESSIVE GEP-NETS TREATED WITH 177LU-OCTREOTATE
    Park, J.
    Browne, E.
    Cluff, A.
    Butler, S. P.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 17 - 17
  • [6] Towards dose-response relationship in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs) treated with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT)
    Marin, G.
    Levillain, H.
    Karfis, I.
    Marin, C.
    Vanderlinden, B.
    Reynaert, N.
    Vandenberghe, S.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S591 - S592
  • [7] PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) - The Rotterdam Cohort
    Van der Zwan, W.
    Brabander, T.
    Kam, B.
    Teunissen, J.
    Krenning, E.
    Kwekkeboom, D.
    de Herder, W.
    NEUROENDOCRINOLOGY, 2018, 106 : 262 - 262
  • [8] Outcome prediction in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT): results from a prospective phase II clinical trial
    Mileva, M.
    Marin, G.
    Levillain, H.
    Artigas, C.
    Van Bogaert, C.
    Marin, C.
    Danieli, R.
    Deleporte, A.
    Jungels, C.
    Vanderlinden, B.
    Wimana, Z.
    Hendlisz, A.
    Flamen, P.
    Karfis, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S106 - S106
  • [9] 177LU-DOTATATE IN PATIENTS WITH RECURRENT MENINGIOMA
    Nasrollahi, Elham
    Drappatz, Jan
    NEURO-ONCOLOGY, 2024, 26
  • [10] External dose assessment from the patients treated by 177Lu-DOTATATE
    Mahmoudi, E.
    Amoui, M.
    Deevband, M. R.
    Pirayesh, E.
    Rad, M. Ghorbani
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2022, 20 (01): : 235 - 239
12345